News Quantified

OTLK – outlook therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Oncobiologics (NASDAQ:OTLK) had its price target raised by analysts at Ascendiant Capital Markets from $8.00 to $10.00. They now have a "buy" rating on the stock.

Outlook Therapeutics Reports Financial Results for Fiscal Year 2025 [Yahoo! Finance]

Outlook Therapeutics Reports Financial Results for Fiscal Year 2025

Oncobiologics (NASDAQ:OTLK) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.

Oncobiologics (NASDAQ:OTLK) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.

15.7%

MISS

3.9%

MISS

1.6%

MISS

-1.6%

MISS

Ascendiant Capital

Form 10-K Outlook Therapeutics, For: Sep 30

Form 8-K Outlook Therapeutics, For: Dec 19

Form 8-K Outlook Therapeutics, For: Nov 03

Form SCHEDULE 13G/A Outlook Therapeutics, Filed by: Empery Asset Management, LP

Form 4 Outlook Therapeutics, For: Oct 01 Filed by: Huang Andong

Top News Gainers

5/15 Form 10-Q Outlook Therapeutics, For: Mar 31 62.8%

12/31 Form 4 Outlook Therapeutics, For: Dec 31 Filed by: Pillai Arun Kumar 48.6%

2/24 Outlook Therapeutics Announces $10.2 Million Financings Priced At-The-Market 20.0%

12/3 Outlook Therapeutics Receives FDA Agreement for Three Special Protocol Assessments for Additional Planned Clinical Trials of ONS-5010 16.9%

7/18 Outlook Therapeutics, Inc. (NASDAQ: OTLK) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. 14.8%

12/30 Form 4 Outlook Therapeutics, For: Dec 23 Filed by: Pillai Arun Kumar 13.5%

12/23 Form 8-K Outlook Therapeutics, For: Dec 20 11.3%

5/20 Outlook Therapeutics: A Perfect Storm Of Positive Catalysts Driving Share Price Up [Seeking Alpha] 11.1%

4/15 Outlook Therapeutics to Present at the April 2020 Virtual Investor Summit 9.2%

9/11 Outlook Therapeutics to Present at the 29th Annual Ladenburg Thalmann 2019 Healthcare Conference 7.3%

Top News Decliners

12/23 Outlook Therapeutics Announces Warrant Amendment and Restructuring of Senior Secured Notes in Separate Transactions -50.0%

1/28 Outlook Therapeutics Announces Agreements to Streamline Capital Structure and Regain 100% Ownership of Any Future Net Profits for ONS-5010 -15.0%

12/3 Outlook Therapeutics up 49% on advancement of ONS-5010 [Seeking Alpha] -14.0%

8/27 Outlook Therapeutics to Present at the H.C. Wainwright 21st Annual Healthcare Conference -12.6%

5/15 Q2/2019 3/31/2019 EPS -0.580 ZacksConsensus N/A ActVsEst N/A - N/A -9.9%

5/17 Outlook Therapeutics' stock rockets on heavy volume again, has more than doubled in 2 days [MarketWatch] -9.1%

9/18 Outlook Therapeutics, Inc. (NASDAQ: OTLK) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. -9.0%

6/3 Form S-3 Outlook Therapeutics, -7.3%

2/24 Form 424B5 Outlook Therapeutics, -7.3%

6/14 Form 8-K Outlook Therapeutics, For: Jun 11 -7.3%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day